Abstract
Chemotherapeutics (CHTs) can induce a variety of hypersensitivity reactions (HSRs) that may be severe and affect further oncology treatments. Basophil activation test (BAT) could help to endotype these patients safely, but its diagnostic utility remains unknown. We aimed to evaluate the utility of BAT in our population.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
